SSA
AXSM icon

Schonfeld Strategic Advisors’s Axsome Therapeutics AXSM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$1.65M – 2140
2021
Q3 		$1.65M Buy
+50,000
New +$1.95M 0.02% 781

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schonfeld Strategic Advisors's AXSM Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 2,490 shares — an estimated $260K sold.

Schonfeld Strategic Advisors first reported a position in AXSM in Q1 2019 and held it in 21 quarters. The position peaked at $15.7M in Q2 2019. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 2,490 Axsome Therapeutics shares in Q3 2025, an estimated $260K.
  • Schonfeld Strategic Advisors first reported a position in Axsome Therapeutics in Q1 2019 and held it in 21 quarters.
  • Schonfeld Strategic Advisors's Axsome Therapeutics position peaked at $15.7M in Q2 2019.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.